Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (30)

I-08Rubin Lubomirov

Population pharmacokinetic-based interspecies allometric scaling and prediction of first-in-human (FIH) pharmacokinetics of a new anticancer agent

Wednesday 10:30-12:00

I-11Sreenath M Krishnan

Influence of the number of tumor size measurements on model-derived tumor size metrics and prediction of survival

Wednesday 10:30-12:00

I-19

Using mixed effects modelling improves detection of drug-gene interactions in mouse trials

Wednesday 10:30-12:00

I-35Sean Oosterholt

PKPD modelling of MYCN-inhibition in vitro and in vivo in a mouse model of neuroblastoma

Wednesday 10:30-12:00

I-43Sophie Peigné

How to handle non-linearity in absorption: a case study in oncology

Wednesday 10:30-12:00

I-45Belén Pérez Solans

Modelling tumour growth and progression free survival of breast cancer patients treated with neoadjuvant therapy

Wednesday 10:30-12:00

II-21Ajit Suri

Population Pharmacokinetic Modeling of Brentuximab Vedotin, a CD30-Directed Antibody-Drug Conjugate, and its cytotoxic payload (MMAE) in Patients With Various Hematological Malignancies

Wednesday 15:10-16:30

II-25Adrien Tessier

Investigating the PK/PD relationship of a new pro-apoptotic drug through tumor growth inhibition modelling in NUDE rats

Wednesday 15:10-16:30

II-29Elena Tosca

A PK/PD model for tumor-in-host growth kinetics following administration of an antiangiogenic agent given alone or in combination regimens

Wednesday 15:10-16:30

II-46Marc Vandemeulebroecke

Multi-state modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation (allo-HSCT) to inform drug development

Wednesday 15:10-16:30

II-55Sebastian Wicha

The purpose determines the predictive performance: Comparison of four population pharmacokinetic models of methotrexate.

Wednesday 15:10-16:30

II-57Francis Williams Ojara

Examining the relationship between paclitaxel exposure and peripheral neuropathy in non-small cell lung cancer

Wednesday 15:10-16:30

II-60Gudrun Wuerthwein

Population Pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar® in children with ALL

Wednesday 15:10-16:30

II-62Joao Paulo Ximenez

Population pharmacokinetic of tamoxifen and its metabolites in breast cancer patients

Wednesday 15:10-16:30

III-10María García-Cremades

Mechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer

Thursday 09:50-11:20

III-36Itziar Irurzun-Arana

Population PD modelling of circulating biomarkers in patients with melanoma treated with interferon alpha2b

Thursday 09:50-11:20

III-42Martin Johnson

Exposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment

Thursday 09:50-11:20

III-45Matts Kågedal

Herceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels.

Thursday 09:50-11:20

III-51Lena Klopp-Schulze

Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis

Thursday 09:50-11:20

III-57Yuri Kosinsky

Radiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach

Thursday 09:50-11:20

III-59Anu Shilpa Krishnatry

Population pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors

Thursday 09:50-11:20

III-63Silvia Maria Lavezzi

Modelling of rituximab clearance reduction due to ibrutinib co-administration

Thursday 09:50-11:20

IV-06Usman Arshad

Population pharmacokinetic model of mitotane enzyme autoinduction in adrenocortical carcinoma patients

Thursday 14:45-16:15

IV-14Guillaume Baneyx

Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma.

Thursday 14:45-16:15

IV-17Brendan Bender

A Mechanism-Based Model of Tumor Quiescence and Resistance in HER2-Negative Metastatic Breast Cancer in Patients Receiving Docetaxel or Paclitaxel

Thursday 14:45-16:15

IV-19Aliénor Bergès

Dose-exposure-response model between an ATR inhibitor and peripheral monocytes

Thursday 14:45-16:15

IV-28Núria Buil Bruna

Predicting myelosuppression from phase I data: Which model should we use?

Thursday 14:45-16:15

IV-42S. Y. Amy Cheung

Optimising Phase 1 oncology dosing schedule of an ATR inhibitor in real time using a model informed approach to predict myelosuppression

Thursday 14:45-16:15

IV-55Aurelia de Vries Schultink

Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

Thursday 14:45-16:15

IV-61Solène Desmée

Mechanistic joint modelling for longitudinal PSA and survival data in advanced metastatic prostate cancer

Thursday 14:45-16:15